145 related articles for article (PubMed ID: 12920048)
1. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis.
Sobel BE; Taatjes DJ; Schneider DJ
Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):1979-89. PubMed ID: 12920048
[TBL] [Abstract][Full Text] [Related]
2. [Expression of urokinase plasminogen activator, its receptor and plasminogen activator inhibitor type 1 in different types of atherosclerotic lesion in human aorta].
Solomatina MA; Plekhanova OS; Il'inskaia OP; Kalinina NI; Mikhaĭlova EV; Tsokolaeva ZI; Tararak EM; Naumov VG; Parfenova EV
Tsitologiia; 2004; 46(4):352-60. PubMed ID: 15346794
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury.
Fay WP
Trends Cardiovasc Med; 2004 Jul; 14(5):196-202. PubMed ID: 15261892
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen-activator inhibitor type 1 and coronary artery disease.
Kohler HP; Grant PJ
N Engl J Med; 2000 Jun; 342(24):1792-801. PubMed ID: 10853003
[No Abstract] [Full Text] [Related]
5. The 'PAI-1 paradox' in vascular remodeling.
Diebold I; Kraicun D; Bonello S; Görlach A
Thromb Haemost; 2008 Dec; 100(6):984-91. PubMed ID: 19132221
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents.
Muldowney JA; Stringham JR; Levy SE; Gleaves LA; Eren M; Piana RN; Vaughan DE
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):400-6. PubMed ID: 17158352
[TBL] [Abstract][Full Text] [Related]
7. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes.
Sobel BE; Schneider DJ
Cardiol Clin; 2004 Nov; 22(4):511-26. PubMed ID: 15501620
[TBL] [Abstract][Full Text] [Related]
8. Expression of fibrinolysis activators and their inhibitor in neointima of polyester vascular grafts.
Kowalewski R; Zimnoch L; Wojtukiewicz MZ; Glowinski J; Glowinski S
Biomaterials; 2004 Dec; 25(28):5987-93. PubMed ID: 15183613
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Carmassi F; De Negri F; Fioriti R; De Giorgi A; Giannarelli C; Fruzzetti F; Pedrinelli R; Dell'Omo G; Bersi C
Thromb Res; 2005; 116(3):207-14. PubMed ID: 15935829
[TBL] [Abstract][Full Text] [Related]
10. Relationship of adiposity to subclinical atherosclerosis in obese patients with type 2 diabetes.
Hegazi RA; Sutton-Tyrrell K; Evans RW; Kuller LH; Belle S; Yamamoto M; Edmundowicz D; Kelley DE
Obes Res; 2003 Dec; 11(12):1597-605. PubMed ID: 14694226
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension.
Kouri FM; Queisser MA; Königshoff M; Chrobak I; Preissner KT; Seeger W; Eickelberg O
Int J Biochem Cell Biol; 2008; 40(9):1872-82. PubMed ID: 18337154
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways.
Otsuka G; Agah R; Frutkin AD; Wight TN; Dichek DA
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):737-43. PubMed ID: 16373605
[TBL] [Abstract][Full Text] [Related]
13. C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo.
Kairuz EM; Barber MN; Anderson CR; Kanagasundaram M; Drummond GR; Woods RL
Cardiovasc Res; 2005 Jun; 66(3):574-82. PubMed ID: 15914122
[TBL] [Abstract][Full Text] [Related]
14. Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1).
Furumoto T; Fujii S; Nishihara K; Yamada S; Komuro K; Goto K; Onozuka H; Mikami T; Kitabatake A; Sobel BE
Am J Cardiol; 2004 Apr; 93(8):997-1001. PubMed ID: 15081442
[TBL] [Abstract][Full Text] [Related]
15. Rac-1 promotes pulmonary artery smooth muscle cell proliferation by upregulation of plasminogen activator inhibitor-1: role of NFkappaB-dependent hypoxia-inducible factor-1alpha transcription.
Diebold I; Djordjevic T; Hess J; Görlach A
Thromb Haemost; 2008 Dec; 100(6):1021-8. PubMed ID: 19132225
[TBL] [Abstract][Full Text] [Related]
16. The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.
Sobel BE
Proc Assoc Am Physicians; 1999; 111(4):313-8. PubMed ID: 10417739
[TBL] [Abstract][Full Text] [Related]
17. Coronary artery disease and fibrinolysis: from the blood to the vessel wall.
Sobel BE
Thromb Haemost; 1999 Sep; 82 Suppl 1():8-13. PubMed ID: 10695478
[TBL] [Abstract][Full Text] [Related]
18. Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.
Sato Y; Dong J; Imagawa S; Ishimori N; Furumoto T; Tsutsui H; Sobel BE; Fujii S
Coron Artery Dis; 2008 Aug; 19(5):355-61. PubMed ID: 18607173
[TBL] [Abstract][Full Text] [Related]
19. PAI-1 and TGF-beta: unmasking the real driver of TGF-beta-induced vascular pathology.
Vaughan DE
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):679-80. PubMed ID: 16556860
[No Abstract] [Full Text] [Related]
20. Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice.
Schäfer K; Schroeter MR; Dellas C; Puls M; Nitsche M; Weiss E; Hasenfuss G; Konstantinides SV
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1254-9. PubMed ID: 16514083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
